Idiopathic Pulmonary Fibrosis Market: Expanding Revenue Landscape to 2034 - DelveInsight | Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics, Pliant Therapeutics., GSK

The Key Idiopathic Pulmonary Fibrosis Companies in the market inlcude - Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics, Pliant Therapeutics, Inc., GlaxoSmithKline, Amgen, Bristol-Myers Squibb, Endeavor Biomedicines, Syndax Pharmaceuticals, Regend Therapeutics, and others.

DelveInsight's "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Idiopathic Pulmonary Fibrosis, offering comprehensive insights into the Idiopathic Pulmonary Fibrosis revenue trends, prevalence, and treatment landscape. The report delves into key Idiopathic Pulmonary Fibrosis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Idiopathic Pulmonary Fibrosis therapies. Additionally, we cover the landscape of Idiopathic Pulmonary Fibrosis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Idiopathic Pulmonary Fibrosis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Idiopathic Pulmonary Fibrosis space.

Get a Free sample for the Idiopathic Pulmonary Fibrosis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-market [https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Idiopathic Pulmonary Fibrosis Market Report:

*
The Idiopathic Pulmonary Fibrosis market size was valued ~USD 3,300 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).

*
In January 2026, Boehringer Ingelheim has announced the initiation of a Phase IIa clinical study to assess BI 765423, a first-in-class monoclonal antibody directed against interleukin-11 (IL-11), in patients with idiopathic pulmonary fibrosis (IPF). The trial represents an important step in the company's ongoing efforts to develop new treatments for progressive fibrotic lung disorders.

*
In January 2026, Jascayd Registered (nerandomilast/BI 1015550) is a phosphodiesterase-4 (PDE4) inhibitor developed by Boehringer Ingelheim for adult patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). It is positioned as the first and only preferential phosphodiesterase-4B (PDE4B) inhibitor approved for IPF treatment in adults. The therapy is marketed as oval, biconvex, film-coated tablets available in 9 mg light-yellow and 18 mg light-red strengths.

*
In September 2025, United Therapeutics is seeking approval for Tyvaso (treprostinil) in idiopathic pulmonary fibrosis (IPF) following positive results from a Phase III trial. In the TETON-2 study (NCT05255991), the inhaled prostacyclin mimetic significantly improved forced vital capacity (FVC), showing a 95.6 mL increase from baseline. Since FVC is a crucial indicator of breathing restriction in IPF, this outcome is notable. Additionally, the systemic vasodilator delayed the time to the first clinical worsening event, achieving its key secondary endpoint.

*
In May 2025, Endeavor BioMedicines, a clinical-stage biotech company developing treatments for serious conditions, presented a post hoc analysis from its completed Phase 2a trial of the investigational drug ENV-101 (taladegib). The findings indicated that patients with idiopathic pulmonary fibrosis (IPF) treated with ENV-101 for 12 weeks showed a marked reduction in pulmonary vessel volume, a significant increase in lung volume, and a trend toward decreased lung fibrosis compared to placebo. This analysis, utilizing Qureight's advanced deep learning CT technology, was highlighted in a poster presentation at the ATS 2025 International Conference.

*
In February 2025, Pliant Therapeutics, Inc. (Nasdaq: PLRX) has temporarily halted enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis (IPF) following a prespecified data review and recommendations from the independent Data Safety Monitoring Board (DSMB). However, patients already enrolled will continue participation in the trial.

*
In January 2025, Mediar Therapeutics entered into a global licensing agreement with Eli Lilly and Company to progress MTX-463 into a Phase II clinical trial for idiopathic pulmonary fibrosis (IPF). MTX-463 is a novel human IgG1 antibody designed to inhibit WISP1-driven fibrotic signaling associated with multiple severe diseases.

*
In December 2024, Boston-based clinical-stage biotherapeutics company PureTech announced that its Phase IIb trial of deupirfenidone successfully met all primary and secondary endpoints, demonstrating a reduction in lung function decline in patients with idiopathic pulmonary fibrosis (IPF). The dose-ranging study assessed deupirfenidone (LYT-100) over 26 days, revealing that the high dose effectively slowed lung degeneration. PureTech aims to position the therapy as a new standard of care (SOC) for IPF

*
In September 2024, Insilico Medicine reported positive initial findings from its Phase IIa clinical trial of ISM001-055, a generative AI-designed small molecule drug for idiopathic pulmonary fibrosis (IPF). The randomized, double-blind, placebo-controlled study was conducted at 21 sites in China, enrolling 71 IPF patients. The trial evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of 12-week oral treatment with ISM001-055.

*
In 2023, the Idiopathic Pulmonary Fibrosis market in the EU4 and the UK was approximately USD 702 million, representing around 21% of the total market size across the 7MM.

*
In the EU4 and the UK, Germany had the largest market size, approximately USD 183 million, followed by the UK at around USD 141 million and France at USD 140 million. These figures are expected to evolve during the forecast period.

*
Key Idiopathic Pulmonary Fibrosis Companies: Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics, Pliant Therapeutics, Inc., GlaxoSmithKline, Amgen, Bristol-Myers Squibb, Endeavor Biomedicines, Syndax Pharmaceuticals, Regend Therapeutics, and others

*
Key Idiopathic Pulmonary Fibrosis Therapies: BI 1015550, OFEV (Nintedanib), Pirfenidone, SC1011, TTI-101, PLN-74809, GSK3915393, HZN-825, BMS-986278, taladegib, BI 181947, Axatilimab, REGEND001, and others

*
The Idiopathic Pulmonary Fibrosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Idiopathic Pulmonary Fibrosis pipeline products will significantly revolutionize the Idiopathic Pulmonary Fibrosis market dynamics.

*
The total number of diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis in the 7MM was estimated to be around 193,000 in 2023. This figure is projected to rise in the coming years, driven by an aging population and advancements in diagnostic methods.

*
In 2023, the US had the highest number of diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis among the 7MM, with around 95,000 cases. This number is projected to grow throughout the forecast period from 2024 to 2034.

*
Germany had the highest number of diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis among the EU4 and the UK, with nearly 21,000 cases. It was followed by the UK and France, with approximately 15,700 and 15,500 diagnosed prevalent cases, respectively.

Idiopathic Pulmonary Fibrosis Overview

Idiopathic Pulmonary Fibrosis (IPF) is a chronic and progressive lung disease characterized by the scarring or thickening of lung tissue, which leads to difficulty breathing. The cause of IPF is unknown ("idiopathic"), and it primarily affects older adults. The scarring reduces the lung's ability to transfer oxygen to the bloodstream, causing symptoms such as shortness of breath, persistent cough, and fatigue. Treatment options are limited, but include medications to slow disease progression and manage symptoms.

To Know in detail about the Idiopathic Pulmonary Fibrosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Idiopathic Pulmonary Fibrosis Market Forecast [https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Idiopathic Pulmonary Fibrosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Idiopathic Pulmonary Fibrosis Epidemiology Segmentation:

The Idiopathic Pulmonary Fibrosis market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Idiopathic Pulmonary Fibrosis

*
Prevalent Cases of Idiopathic Pulmonary Fibrosis by severity

*
Gender-specific Prevalence of Idiopathic Pulmonary Fibrosis

*
Diagnosed Cases of Episodic and Chronic Idiopathic Pulmonary Fibrosis

Download the report to understand which factors are driving Idiopathic Pulmonary Fibrosis epidemiology trends @ Idiopathic Pulmonary Fibrosis Epidemiology Forecast [https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Idiopathic Pulmonary Fibrosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Idiopathic Pulmonary Fibrosis market or expected to get launched during the study period. The analysis covers Idiopathic Pulmonary Fibrosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Idiopathic Pulmonary Fibrosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Idiopathic Pulmonary Fibrosis Therapies and Key Companies

*
BI 1015550: Boehringer Ingelheim

*
OFEV (Nintedanib): Boehringer Ingelheim Pharma GmbH

*
Pirfenidone: PureTech

*
SC1011: Guangzhou JOYO Pharma

*
TTI-101: Tvardi Therapeutics

*
PLN-74809: Pliant Therapeutics, Inc.

*
GSK3915393: GlaxoSmithKline

*
HZN-825: Amgen

*
BMS-986278: Bristol-Myers Squibb

*
taladegib: Endeavor Biomedicines

*
BI 1819479: Boehringer Ingelheim

*
Axatilimab: Syndax Pharmaceuticals

*
REGEND001: Regend Therapeutics

Discover more about therapies set to grab major Idiopathic Pulmonary Fibrosis market share @ Idiopathic Pulmonary Fibrosis Treatment Landscape [https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Idiopathic Pulmonary Fibrosis Market Drivers

*
Increasing Prevalence

*
Advances in Research and Development

*
Approval of New Drugs

*
Improved Diagnostic Techniques

*
Rising Healthcare Awareness

*
Aging Population

Idiopathic Pulmonary Fibrosis Market Barriers

*
High Treatment Costs

*
Limited Effective Therapies

*
Adverse Effects of Existing Treatments

*
Late Diagnosis

*
Complex Regulatory Approvals

*
Lack of Awareness in Developing Regions

Scope of the Idiopathic Pulmonary Fibrosis Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Idiopathic Pulmonary Fibrosis Companies: Boehringer Ingelheim, PureTech, Guangzhou JOYO Pharma, Tvardi Therapeutics, Pliant Therapeutics, Inc., GlaxoSmithKline, Amgen, Bristol-Myers Squibb, Endeavor Biomedicines, Syndax Pharmaceuticals, Regend Therapeutics, and others

*
Key Idiopathic Pulmonary Fibrosis Therapies: BI 1015550, OFEV (Nintedanib), Pirfenidone, SC1011, TTI-101, PLN-74809, GSK3915393, HZN-825, BMS-986278, taladegib, BI 181947, Axatilimab, REGEND001, and others

*
Idiopathic Pulmonary Fibrosis Therapeutic Assessment: Idiopathic Pulmonary Fibrosis current marketed and Idiopathic Pulmonary Fibrosis emerging therapies

*
Idiopathic Pulmonary Fibrosis Market Dynamics: Idiopathic Pulmonary Fibrosis market drivers and Idiopathic Pulmonary Fibrosis market barriers

*
Idiopathic Pulmonary Fibrosis Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Idiopathic Pulmonary Fibrosis Unmet Needs, KOL's views, Analyst's views, Idiopathic Pulmonary Fibrosis Market Access and Reimbursement

To know more about Idiopathic Pulmonary Fibrosis companies working in the treatment market, visit @ Idiopathic Pulmonary Fibrosis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/idiopathic-pulmonary-fibrosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Idiopathic Pulmonary Fibrosis Market Report Introduction

2. Executive Summary for Idiopathic Pulmonary Fibrosis

3. SWOT analysis of Idiopathic Pulmonary Fibrosis

4. Idiopathic Pulmonary Fibrosis Patient Share (%) Overview at a Glance

5. Idiopathic Pulmonary Fibrosis Market Overview at a Glance

6. Idiopathic Pulmonary Fibrosis Disease Background and Overview

7. Idiopathic Pulmonary Fibrosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Idiopathic Pulmonary Fibrosis

9. Idiopathic Pulmonary Fibrosis Current Treatment and Medical Practices

10. Idiopathic Pulmonary Fibrosis Unmet Needs

11. Idiopathic Pulmonary Fibrosis Emerging Therapies

12. Idiopathic Pulmonary Fibrosis Market Outlook

13. Country-Wise Idiopathic Pulmonary Fibrosis Market Analysis (2020-2034)

14. Idiopathic Pulmonary Fibrosis Market Access and Reimbursement of Therapies

15. Idiopathic Pulmonary Fibrosis Market Drivers

16. Idiopathic Pulmonary Fibrosis Market Barriers

17. Idiopathic Pulmonary Fibrosis Appendix

18. Idiopathic Pulmonary Fibrosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=idiopathic-pulmonary-fibrosis-market-expanding-revenue-landscape-to-2034-delveinsight-boehringer-ingelheim-puretech-guangzhou-joyo-pharma-tvardi-therapeutics-pliant-therapeutics-gsk]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.